Solventum under pressure to prove growth in earnings report By Investing.com

Solventum (SOLV) is under pressure to demonstrate sustained organic growth in its upcoming second-quarter earnings report. Investors are focused on whether the medical technology company can accelerate sales growth across its segments and improve profitability, especially given analyst concerns about its weak growth outlook and pricing pressures in the healthcare industry. Despite outperforming Wall Street's price target, the market expects modest growth, making any positive surprise potentially significant for the company.